Amgen (NASDAQ:AMGN) Stock Falls 9% to $397.77 on September 8: Lp(a) Pipeline Concerns
Amgen shares fell 9.0% to $397.77 on September 8 after Novartis' Lp(a) trial failure cast doubt on the drug class Amgen is also pursuing. A BMO Capital downgrade to Market Perform compounded

Follow